Olatec Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
800 5th Ave Apt 25D, New York, New York,...Website
www.olatec.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Olatec Therapeutics
Olatec is a privately held biopharmaceutical company focused on the clinical development of NLRP3 antagonist therapeutics aimed at treating a wide range of inflammatory diseases, including arthritis, heart failure, and various cancers. Their lead compound, dapansutrile, has shown clinical benefits in reducing systemic inflammation and has a favorable safety profile. The company boasts a robust pipeline of approximately 40 pharmaceutical candidates and a strong intellectual property portfolio with over 180 patents globally. Olatec's experienced management team includes international thought leaders in inflammation and immunology, enhancing their capabilities in drug development.Explore more
Olatec Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Olatec Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Olatec Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Olatec Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Olatec Therapeutics
Olatec Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Olatec Therapeutics launches new products
Click to see if Olatec Therapeutics had a recent Job posting/layoffs
Check out if Olatec Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Olatec Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Olatec Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Olatec Therapeutics
Compare insights from companies similar to Olatec Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Olatec Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Olatec Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Olatec Therapeutics.
Olatec Therapeutics financials insights
Gather financial insights about Olatec Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$40M
Olatec Therapeutics Tech Stack
A closer look at the technologies used by Olatec Therapeutics
See more technologies
Most Recent Scoops
Funding
Executive Move
Board of Directors
Executive Move
Board of Directors
New Hire
Executive Move
Left Company
Executive Move
Olatec Therapeutics News & Media
First Parkinson's Patients Treated in Landmark Phase 2 Trial of Dapansutrile - Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases
NEW YORK, March 24, 2026 /PRNewswire/ -- Olatec Therapeutics, Inc. ("Olatec"), developing one of the most clinically advanced specific oral NLRP3 inhibitors, dapansutrile, today announced that two patients have been randomized in a 12-month clinical trial, named DAPA-PD, for the treatment...Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies
NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Olatec Therapeutics, Inc. ("Olatec"), a clinical stage biotechnology company leading the development of specific NLRP3 inhibitors, presented preclinical data at The Michael J. Fox Foundation (MJFF) Parkinson's Disease Research Exchange forum. The...Andy Cunningham Joins Olatec Therapeutics Board of Directors
NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Olatec Therapeutics, Inc., a leader in the emerging class of specific NLRP3 inhibitors, today announced that Andy Cunningham had joined its Board of Directors. She succeeds Valentín Campos, who retired from the Board after 9 years of service. Ms....Marc Y. Donath MD, Renowned Immuno-Endocrinologist, Appointed to Olatec’s Clinical Advisory Board
NEW YORK--(BUSINESS WIRE)-- #COVID19--Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, today announced that long-time collaborator and advisor, Prof. Dr. Marc Donath, has joined the Company’s Clinical Advisory Board (CAB). Dr. Donath, a renowned immuno-endocrinologist, has been recently elected as Medical Director of the Diabetes Centre at the University Hospital Montreal, Canada and is Chief Physician in Endocrinology, Diabetes and Metabolism at the Uni
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Olatec Therapeutics
Sign Up For FreeTo access detailed company insights
Olatec is a privately held biopharmaceutical company focused on the clinical development of NLRP3 antagonist therapeutics aimed at treating a wide range of inflammatory diseases, including arthritis, heart failure, and various cancers. Their lead compound, dapansutrile, has shown clinical benefits in reducing systemic inflammation and has a favorab... Read More
